Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | PKM | P14618 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31217438 | 0.87 | ALDH1A1 (0.51) | ALDH1A1LMNAPKMPOLBMEN1 | |
| SCHEMBL31217320 | 0.85 | ALDH1A1 (0.48) | ALDH1A1LMNAPKMPOLBMEN1 | |
| SCHEMBL26890594 | 0.84 | ALDH1A1 (0.54) | ALDH1A1LMNAPKMPOLBMEN1 | |
| SCHEMBL2519991 | 0.84 | ALDH1A1 (0.54) | ALDH1A1LMNAPKMPOLBMEN1 | |
| SCHEMBL30502812 | 0.84 | ALDH1A1 (0.54) | ALDH1A1LMNAPKMPOLBMEN1 | |
| SCHEMBL25434397 | 0.83 | ALDH1A1 (0.56) | ALDH1A1LMNAPKMPOLBMEN1 | |
| SCHEMBL25433999 | 0.83 | ALDH1A1 (0.53) | ALDH1A1LMNAPKMPOLBMEN1 | |
| SCHEMBL25433128 | 0.82 | ALDH1A1 (0.54) | ALDH1A1LMNAPKMPOLBMEN1 | |
| SCHEMBL25434818 | 0.81 | ALDH1A1 (0.50) | ALDH1A1LMNAPKMPOLBMEN1 | |
| SCHEMBL2520783 | 0.80 | PKM (0.47) | ALDH1A1LMNAPKMPOLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624052-B2 | KRAS modulators and uses thereof | QUANTA THERAPEUTICS, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| EP-4709729-A1 | PYRAZOLO[4,3-F]QUINAZOLINE DERIVATIVES AS MODULATORS OF G12D MUTANT KRAS USEFUL FOR THE TREATMENT OF CANCER | Jazz Pharmaceuticals Ireland Ltd. (IE) | 2026-03-18 | — | — | EP | disclosed |
| US-20250243222-A1 | PYRIMIDINE BASED MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS, INC. | 2025-07-31 | — | — | US | disclosed |
| WO-2025106901-A1 | COMBINATION CANCER THERAPIES WITH A KRAS MODULATOR AND AN RTK-MAPK PATHWAY INHIBITOR | QUANTA THERAPEUTICS, INC. (US) | 2025-05-22 | — | — | WO | disclosed |
| WO-2025106905-A1 | COMBINATION THERAPIES WITH A KRAS MODULATOR AND AN IMMUNOMODULATOR INHIBITOR | QUANTA THERAPEUTICS, INC. (US) | 2025-05-22 | — | — | WO | disclosed |
| EP-4532494-A1 | PYRIMIDINE BASED MODULATORS AND USES THEREOF | Quanta Therapeutics, Inc. (US) | 2025-04-09 | — | — | EP | disclosed |
| WO-2025034883-A1 | COMBINATION THERAPIES WITH KRAS MODULATORS | QUANTA THERAPEUTICS, INC. (US) | 2025-02-13 | — | — | WO | disclosed |
| WO-2025034919-A1 | COMBINATION THERAPIES WITH KRAS MODULATORS | QUANTA THERAPEUTICS, INC. (US) | 2025-02-13 | — | — | WO | disclosed |
| US-20250042921-A1 | KRAS MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS, INC. | 2025-02-06 | — | — | US | disclosed |
| EP-4475956-A1 | KRAS MODULATORS AND USES THEREOF | Quanta Therapeutics, Inc. (US) | 2024-12-18 | — | — | EP | disclosed |
| WO-2024236452-A1 | PYRAZOLO[4,3-F]QUINAZOLINE DERIVATIVES AS MODULATORS OF G12D MUTANT KRAS USEFUL FOR THE TREATMENT OF CANCER | JAZZ PHARMACEUTICALS IRELAND LTD. (IE) | 2024-11-21 | — | — | WO | disclosed |
| US-12145947-B2 | Pyrimidine based modulators and uses thereof | QUANTA THERAPEUTICS, INC. (US) | 2024-11-19 | — | — | US | disclosed |
| US-20240199650-A1 | PYRIMIDINE BASED MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS, INC. | 2024-06-20 | — | — | US | disclosed |
| US-11912723-B2 | KRAS modulators and uses thereof | QUANTA THERAPEUTICS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| WO-2023230190-A1 | PYRIMIDINE BASED MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS, INC. (US) | 2023-11-30 | — | — | WO | disclosed |
| US-20230374042-A1 | KRAS MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| WO-2023154766-A1 | KRAS MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12145947-B2 | Pyrimidine based modulators and uses thereof | KRAS, NRAS, DPYD | ALDH1A1 1020/4885LMNA 3966/4885PKM 2765/4885 |
| US-20250243222-A1 | PYRIMIDINE BASED MODULATORS AND USES THEREOF | KRAS, NRAS, DPYD | ALDH1A1 1020/4885LMNA 3966/4885PKM 2765/4885 |
| US-20240199650-A1 | PYRIMIDINE BASED MODULATORS AND USES THEREOF | KRAS, NRAS, DPYD | ALDH1A1 1020/4885LMNA 3966/4885PKM 2765/4885 |
| US-20250042921-A1 | KRAS MODULATORS AND USES THEREOF | KRAS, NRAS, HRAS | ALDH1A1 3974/4885LMNA 3992/4885PKM 2363/4885 |
| US-20230374042-A1 | KRAS MODULATORS AND USES THEREOF | KRAS, NRAS, HRAS | ALDH1A1 3733/4885LMNA 4214/4885PKM 2837/4885 |
| US-12624052-B2 | KRAS modulators and uses thereof | KRAS, NRAS, HRAS | ALDH1A1 3044/4885LMNA 3905/4885PKM 4720/4885 |
| US-11912723-B2 | KRAS modulators and uses thereof | KRAS, NRAS, HRAS | ALDH1A1 3733/4885LMNA 4214/4885PKM 2837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.